VIGONVITA-B

2630
72.8500.28% ( +0.200 )
Delay Closed: Nov 16, 16:08:11

Overview

VIGONVITA-B (2630)

Vigonvita Life Sciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for neurops...

Open
72.800
High
73.650
Low
69.000
Prev. Close
72.650
Volume
226.20K
Turnover
16.46M
Avg Price
72.746
Bid/Ask Ratio
-90.91%
Amplitude
6.40%
52wk High
134.900
Volume Ratio
2.90
Turnover Ratio
0.14%
52wk Low
52.000
HK Mkt Cap
12.09B
Market CapHKD
12.14B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-2.11
EPSDynamic
-1.69
EPSStatic
--
BVPS
1.48
P/B
49.16
HK Shares
165.97M
Dividend YieldTTM
--
DividendTTM
--
Shares
166.67M
Min lot size
200
Currency
HKD

Daily Events

  1. Nov, 16

    TPN171's Hong Kong and Macau filings being accepted, alongside repeated share-repurchase disclosures, failed to absorb profit-taking, and the stock traced a deep V today: it fell 5.0% to HK$69.00 by 10:22, rebounded to HK$73.00 at 13:51 before easing to close at HK$71.90, down about 1.0% on 226,600 shares worth HK$16.48 million. Operations are improving off a low base, with Q2 2026 revenue of HK$76.1 million, up 736.58% year on year, while the net loss narrowed 25.63% to HK$70.5 million, leaving net margin at -92.64% and EPS at -HK$0.4216. The price sits 46% below its 52-week high of HK$134.90 and 13.33% lower year to date, beneath the MA20 of HK$75.62 and MA60 of HK$82.28, with PB at 49.16 times against a HK$12.14 billion market value. Though last week's 21.39% rebound shows buybacks and filing progress can still move the tape quickly.

  2. Nov, 13

    Vigonvita (2630.HK) reversed early gains even after TPN171 NDAs were accepted in Hong Kong and Macau, opening at HK$75.50, the session high, then sliding to HK$70.70 by 14:31 BJ and settling near HK$72.05 with the latest print at HK$72.75, about 3% below the prior HK$75.00 close on roughly 127,000 shares. The move extends a choppy stretch: the stock fell 10% on 6 November and 13% on 9 November despite near-daily buyback disclosures, leaving the week down 12.96%, while 10 November brought a 12% rebound. Q2 2026 revenue reached HK$76.1 million, up 736.58% year on year, and the net loss narrowed 25.63% to HK$70.5 million, yet the net margin stayed at -92.64% with a loss of HK$0.4216 per share; PB is 49.12x against a negative PE. The shares sit below the MA20 of HK$75.94 and MA60 of HK$82.50, down 13.44% year to date and 46.07% under the 22 February high of HK$134.90, though still 42.65% above the HK$51.00 low.

  3. Nov, 11

    Vigonvita (2630.HK) opened at HK$70.0 and ground higher through the session to HK$74.7 by 15:58 BJ, then gave back part of the gain to close at HK$73.2, up 4.13%, on only 22,200 shares and HK$1.65 million of turnover. The move follows a 12.96% weekly slide in which repeated share-buyback disclosures failed to stop the decline, so the rebound looks more like a technical repair after the drop than a return of real money. Fundamentals cut both ways: Q2 2026 revenue reached HK$76.1 million, up 736.58% year on year, and the net loss narrowed 25.63% to HK$70.5 million, yet net margin is still -92.64%, loss per share -HK$0.4216, ROE -113.81%, with a 49.49x price-to-book against a negative P/E. At HK$73.2 the stock sits 45.74% below its 52-week high of HK$134.9 and down 12.91% year to date, under both the MA20 of HK$76.64 and MA60 of HK$82.89. Though a turnover rate of just 0.01% means the thin float can exaggerate single-day swings.

  4. Nov, 10

    Vigonvita-B (2630.HK) reversed an early dip to close up 17.2% at HK$70.15 versus the prior close of HK$59.85, on 956,200 shares and HK$58.55 million turnover, as all pre-IPO investors including the controlling shareholder voluntarily extended their lock-up period, extending a buyback run of about 460,200 shares worth roughly HK$36.12 million between November 2 and 6. The session traced a low-open, high-close pattern: a morning low of HK$60.25 at 09:30, then acceleration through the afternoon to an intraday peak of HK$70.35 at 15:46, following a 12.96% weekly decline. Q2 2026 revenue reached HK$76.1 million, up 736.58% year on year, while the net loss narrowed 25.63% to HK$70.5 million at a -92.64% net margin. Even after today's move the price stays below the MA20 of HK$76.9 and MA60 of HK$83.18, down 16.54% year to date and 48% below the 52-week high of HK$134.9. Though a 47.43x price-to-book and negative PE keep the stock sensitive to delivery on that revenue growth.

  5. Nov, 9

    A second straight session of heavy selling: after sliding 12.96% last week, the stock dropped 13.5% to HK$59.85, tracing a spike-and-fade pattern that stalled at HK$69.20 in the morning session, gave back all morning gains, and ground down to HK$60.00 in the afternoon, closing near the session low. Volume was thin at 87,800 shares and HK$5.53 million turnover, a 0.05% turnover rate, with poor liquidity amplifying the move. Fundamentals cut against the tape: Q2 2026 revenue reached HK$76.1 million, up 736.58% year on year, while the net loss narrowed 25.63% to HK$70.5 million and net margin stayed at -92.64%. On price position, the shares sit 55.63% below the 52-week high of HK$134.90, down 28.79% year to date, below both MA20 of HK$77.46 and MA60 of HK$83.56, and only 17% above the HK$51 low. Though buybacks ran daily from November 2 to 6, including 133,600 shares for HK$10.38 million on November 6, and pre-IPO investors including the controlling shareholder voluntarily extended lock-ups, offering some support.

News

Bullish vs. Bearish — Last 3 Months

9.0k followers · 1 opinions
▲Bullish100%
  • L
    lauracharlie

    $VIGONVITA-B(02630.HK)definitely go up